Oxford BioTherapeutics' OGAP platform, a cancer specific membrane protein library, has enabled the company to find cancer targets for its own pipeline and partners alike
CEO Christian Rohlff describes the expertise the company has build and describes pipeline assets, including partnerships with Boehringer, Immunogen, and more.
Comments